EAU 2013 - Programme Book - YouMed

Monday, 18 March - EAU Programme
Abstract Session
09.15 - 10.45 Urothelial cancer treatment: Intravesical approaches
Brown Hall 3 - Level S2
Poster Session 58
Chairs: A. Noon, Sheffield (GB)
M. Rouprêt, Paris (FR)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
697 Prognostic factors and risk groups in T1G3 patients initially treated with BCG: Results of a multicenter
retrospective series in 1743 patients
P. Gontero, R. Sylvester, F. Pisano, S. Joniau, K. Van Der Eeckt, V. Serretta, S. Larré, S. Di Stasi, B. Van Rhijn,
A. Witjes, A. Grotenhuis, R. Colombo, A. Briganti, M. Babjuk, V. Soukup, P.U. Malmstrom, J. Irani, N. Malats,
J. Baniel, R. Mano, T. Cai, E. Cha, P. Ardelt, J. Varkarakis, R. Bartoletti, M. Spahn, G. Dalbagni, S. Shariat,
J. Karnes, J. Palou (Turin, Palermo, Rome, Milan, Trento, Florence, Italy; Brussels, Leuven, Belgium; Oxford,
United Kingdom; Amsterdam, Nijmegen, The Netherlands; Prague, Czech Republic; Uppsala, Sweden;
Poitiers, France; Madrid, Barcelona, Spain; Tel Aviv, Israel; New York, Rochester, United States of America;
Freiburg, Würzburg, Germany; Athens, Greece)
698 Intravesical sequential BCG and electromotive mitomycin versus BCG alone for stage pT1 urothelial bladder
cancer
S.M. Di Stasi, C. Verri, E. Liberati, F. Masedu, M. Valenti (Rome, L’Aquila, Italy)
699 A prospective comparative study of intravesical Bacillus Calmette-Guérin therapy for non-muscle invasive
bladder cancer: Tokyo strain vs Connaught strain
A. Sengiku, M. Ito, Y. Miyazaki, H. Sawazaki, T. Takahashi, K. Ogura (Otsu, Japan)
700 Results of a phase-1 dose escalation study of intravesical TMX-101 in patients with non-muscle invasive
bladder cancer
J. Falke, J.M. Lammers, H.C. Arentsen, M. Ravic, R. Pozzi, E.B. Cornel, H. Vergunst, T.M. De Reijke, J.A. Witjes
(Nijmegen, Hengelo, Amsterdam, The Netherlands; London, United Kingdom; Bioggio, Switzerland)
701 Statin use is not associated with prognosis or BCG-response in patients with non-muscle invasive bladder
cancer
E.N. Xylinas, J.J Crivelli, L.A Kluth, N. Passoni, S. Holmang, P.I. Karakiewicz, E. Comploj, A. Pycha, Y. Lotan,
M. Zerbib, D.S. Scherr, S.F. Shariat (New York, Dallas, United States of America; Milan, Bolzano, Italy;
Gothenburg, Sweden; Montreal, Canada; Paris, France)
702 Is there any influence on the real number of BCG instillations applied on the outcome of high-grade nonmuscle-invasive
bladder cancer (NMIBC)?
J.A. Portillo Martin, R. Madero, E. Solsona, J.M. Fernández, L. Martínez-Piñeiro, M. Montesino, M. Unda,
A. Ojea, J. Rodríguez, J. Palou, J.A. Martínez-Piñeiro (Santander, Madrid, Valencia, Oviedo, Pamplona,
Bilbao, Vigo, Barcelona, Spain)
703 Flow cytometry based immunoassay to monitor the BCG-therapy of the non muscle invasive bladder
cancer
J. Elsaesser, M. Janssen, F. Becker, H. Suttmann, C-H. Ohlmann, U. Sester, M. Stöckle, M. Sester (Homburg,
Neunkirchen, Hamburg, Germany)
EAU Milan 2013
239
Monday